HER-2 directed therapies across gastrointestinal tract cancers - A new frontier.
Loading...
Embargo End Date
ICR Authors
Authors
Jones, L
Cunningham, D
Starling, N
Cunningham, D
Starling, N
Document Type
Journal Article
Date
2024-09-01
Date Accepted
2024-06-18
Abstract
Gastrointestinal (GI) cancers are common and in the metastatic setting they have a poor prognosis. The current mainstay of treatment of GI cancers is chemotherapy; however, the biomarker-directed treatment landscape is evolving. HER-2 is overexpressed in a portion of GI cancers and is an emerging target for therapy, with recent FDA tumor agnostic approval for trastuzumab deruxtecan. Testing for HER-2 expression is not standardized across GI cancers, methodology requires further optimization and standardization as HER-2 targeted therapy emerges into the treatment landscape. There is established rationale for use of HER-2 targeted therapy in first line treatment of metastatic gastric cancer, and emerging evidence with variable benefit in bile duct, pancreatic and colorectal cancers.
Citation
Cancer Treatment Reviews, 2024, 129 pp. 102789 -
Source Title
Cancer Treatment Reviews
Publisher
ELSEVIER SCI LTD
ISSN
0305-7372
eISSN
1532-1967
1532-1967
1532-1967
Collections
Research Team
Medicine (RMH)